Cullinan Associates’s Viatris VTRS Stock Holding History

Cullinan Associates’s Portfolio VTRS Stock Details VTRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-29,539	Closed	-$554K	–	219
2020 Q4	$554K	Buy	+29,539	New	+$482K	0.03%	144

Other funds holding VTRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cullinan Associates's VTRS Position: Q1 2021 in Review

Cullinan Associates sold out of Viatris (VTRS) in Q1 2021, closing a stake of 29,539 shares — an estimated $554K sold.

Cullinan Associates first reported a position in VTRS in Q4 2020 and held it in 1 quarter. The position peaked at $554K in Q4 2020. 1,115 funds tracked by Wall St. Rank hold VTRS as of Q1 2021.

Cullinan Associates reported no remaining Viatris position as of Q1 2021 after selling out during the quarter.
Cullinan Associates sold 29,539 Viatris shares in Q1 2021, an estimated $554K.
Cullinan Associates first reported a position in Viatris in Q4 2020 and held it in 1 quarter.
Cullinan Associates's Viatris position peaked at $554K in Q4 2020.
1,115 funds tracked by Wall St. Rank held Viatris as of Q1 2021.

Based on Cullinan Associates's 13F filing for Q1 2021, filed 20 Apr 2021.